Medical Device Network on MSN2d
Medtronic announces two-year trial outcomes of Evolut TAVR
Medtronic has announced the Small Annuli Randomized To Evolut or SAPIEN (SMART) head-to-head comparative trial’s two-year ...
MassDevice2d
Medtronic has positive TAVR results in small aortic annulus patients
Medtronic released positive two-year trial Evolut TAVR results that demonstrated superior valve performance in small aortic ...
Zacks Investment Research on MSN2d
Positive Trial Data on Evolut TAVR Likely to Support MDT Stock
Medtronic plc MDT recently unveiled two-year Small Annuli Randomized to Evolut or SAPIEN (“SMART”) Trial results at the Cardiovascular Research Technologies (“CRT”) 2025 conference in Washington, D.C.
Medtronic releases two-year results of SMART trial for TAVR
Medtronic (MDT) released the two-year results of the SMall Annuli Randomized To Evolut or SAPIEN, SMART, Trial, the largest international ...
BioWorld1d
Medtronic sees SMART TAVR results in small aortic annulus patients
Medtronic plc released positive results from a two-year trial of Evolut TAVR that demonstrated superior valve performance in patients with small aortic annuli. The SMall Annuli Randomized To Evolut or ...
Nasdaq2d
Medtronic : Data Confirms Superior Valve Performance Of Evolut TAVR System In Small Annulus Patients
(RTTNews) - Medtronic plc (MDT ... as measured by bioprosthetic valve dysfunction (BVD) at two years for Evolut TAVR compared to SAPIEN. The SMART two-year data demonstrated that Evolut TAVR ...
Morningstar3d
SMART Trial two-year data continues to demonstrate superior valve performance for Evolut TAVR™ system in small annulus patients
Additional results demonstrated that Evolut TAVR showed the following relative ... which is part of the Cardiovascular Portfolio at Medtronic. "At two years, we continue to see superior valve ...
PharmiWeb2d
SMART Trial two-year data continues to demonstrate…
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today released the two-year results of the SMall Annuli Randomized To Evolut or SAPIEN (SMART) Trial, the largest international ...
Seeking Alpha21d
Medtronic targets $1B cardiovascular growth in FY25 with PFA expansion
Structural heart products, including the Evolut FX+ TAVR system, showed high-single ... in Hugo robotics and Affera ablation systems. Medtronic reported strong Q3 results, driven by cardiovascular ...
Medindia3d
SMART Trial two-year data continues to demonstrate superior valve performance for Evolut TAVR system in small annulus patients
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today released the two-year results of the SMa ...
Stockhouse2d
SMART Trial two-year data continues to demonstrate superior valve performance for Evolut TAVR(TM) system in small annulus patients
Additional results demonstrated that Evolut TAVR showed the following relative to SAPIEN TAVR ... which is part of the Cardiovascular Portfolio at Medtronic. "At two years, we continue to see superior ...
SMART Trial two-year data continues to demonstrate superior valve performance for Evolut TAVR™ system in small annulus patients
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today released the two-year results of the SMall Annuli Randomized To Evolut or SAPIEN (SMART) Trial, the largest international ...